The current thesis investigated a potential relationship between Alzheimer disease and type-2 diabetes mellitus by analysing early gene expression related to insulin receptor signalling in the hippocampus as well as glucose metabolism in APP/PS1 mice, a model of familial Alzheimer disease. Compared to wild-type animals, a reduction in hippocampal insulin receptor and insulin-receptor substrate 2 transcripts in APP/PS1 mice three-month old as well as an increase in insulin-like growth factor 2 transcripts after six months was detected using real-time polymerase chain reaction. The alterations in hippocampal insulin signalling were accompanied by perturbation of glucose metabolism analysed by intraperitoneal glucose tolerance test. At the age of six months APP/PS1 mice developed glucose intolerance. Learning and recognition memory in APP/PS1 mice were tested using the Novel Object Recognition Test. Cognitive decline became evident in APP/PS1 mice at six months of age. Degradation of both insulin and amyloid β is mediated through insulin-degrading enzyme. However, expression of insulin-degrading enzyme in APP/PS1 mice was notdifferent from wild-type littermates. Changes in hippocampal phosphorylation of the tau phosphoepitopes serine 199, threonine 205, serine 396 and serine 404 were investigated using Western blot. Levels of three phosphoepitopes were increased significantly at either age.IV Protein expression of the phosphorylated form of glycogen synthase kinase 3β remained unchanged indicating an alternative pathway of tau phosphorylation in the APP/PS1 mouse model of familial Alzheimer disease. The current results demonstrate an increase in cyclin-dependant kinase 5 phosphoralyted at tyrosine 15 in APP/PS1 mice at three and six months of age. The correlation between elevated levels of phosphorylated tau and cyclin-dependant kinase 5 suggests that cyclin-dependant kinase 5 might contribute to tau phosphorylation in APP/PS1 mice. In general, this work corroborates common pathologic features in Alzheimer disease and diabetes mellitus. A significant cognitive decline in APP/PS1 mice was associated with changes in early gene expression of insulin-related molecules and perturbations in glucose metabolism. Cyclin-dependant kinase 5 is considered to coregulate tau phosphorylation in APP/PS1 mice, and to be part of a pathway contributing to pathology in Alzheimer disease

Aging and Alzheimer’s disease (AD), are associated with disabling sleep and cognitive deficits. Specifically, aging and Alzheimer’s disease is associated with reduced quantity and quality of the deepest stage of sleep, called slow-wave-sleep (SWS). Interestingly, SWS has been implicated in hippocampus-dependent memory in mice. More importantly, sleep deprivation, aging, and AD are all associated with deficits in memory. Therefore, I hypothesize that, in aging and AD, the sleep deficits are, at least in part, responsible for memory impairments and increasing the quantity and quality of SWS will reverse these memory deficits. I first developed mouse models of SWS enhancement in aging and AD. Chemogenetic activation of the parafacial zone GABAergic neurons enhances SWS in aged mice as previously described in adult mice. Similarly, in AD mice, SWS enhancement is as effective as in littermate wild-type controls. Then, I used these mouse models to characterize the role of SWS in memory using novel gain-of-sleep experiments. I found that acute SWS enhancement: 1) reduce spatial memory in adult mice and 2) failed to improve spatial memory in aged mice. In a preliminary study, acute SWS enhancement seems to improve contextual memory in AD mice. Collectively, my work provides a novel mouse model of SWS enhancement in aging and AD, offering a pivotal tool to study the role of SWS in physiological functions and neurodegenerative diseases. Furthermore, my results suggest that acute SWS enhancement does not benefit the behavioral manifestation of memory consolidation in adult mice and aged mice.

No description available.